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BACKGROUND: Many studies have indicated that colon and rectal cancers differ in etiology 
and histology.  
OBJECTIVE: The aim of this study was to investigate whether the associations of colon and 
rectal cancers with any other (discordant) cancer were site-specific. 
DESIGN: A novel approach was implemented in which cancer risks were analyzed in families 
of increasing numbers of family members diagnosed with defined cancers. The novel assumption 
was that for a true familial association the risk should increase by the number of affected family 
members. In separate analyses familial risks were calculated after exclusion of putative families 
with hereditary non-polyposis colorectal cancer.  
SETTINGS: The study was conducted using the Swedish Family-Cancer Database. 
RESULTS: Relative risks of colorectal cancer and colon cancer were higher when family 
members were diagnosed with colon cancer than when family members were diagnosed with 
rectal cancer (IRRcolonrectal: 1.82 (95%CI 1.74-1.90) vs. 1.61 (95%CI 1.51-1.71) and IRRcolon: 1.92 
(95%CI 1.83-2.02) vs. 1.56 (95%CI 1.45-1.69)). Relative risks for 10 discordant cancers were 
increased in colon or rectal cancer families whereas none of the relative risks differed 
significantly between colon and rectal cancers. After deleting hereditary non-polyposis colorectal 
cancer families, the relative risks of endometrial and ovarian cancers were no longer significant. 
LIMITATIONS: Genetic data are unavailable in the database. 
CONCLUSIONS: Our results suggested that familial risks for colon cancer were higher than 
risks for rectal cancer in families of colorectal cancer and colon cancer patients. The 
relationships of lung cancer and nervous system cancer to colorectal cancer were site-specific. 
The associations of colon and rectal cancers with lung cancer, myeloma and cancer of unknown 











In a paper titled “Rectal and colon cancer: not just a different anatomic site” the authors point out 
that the two cancers differ in their embryological origin and metastatic patterns, in addition to 
many therapy-related factors (1). However, among environmental risk factors only physical 
activity appears to distinguish colon and rectal cancer, as a protective association has been noted 
for colon cancer only (2, 3). The reported familial risk has been higher for colon than rectal 
cancer but according to some studies the difference has been small and not significant (2, 4, 5).  
Among twins, familial risks and heritability estimates for colon and rectal cancers have been 
similar (6).  Hereditary non-polyposis colorectal cancer (HNPCC), the most common colorectal 
cancer (CRC) syndrome, affects preferentially proximal colon but because HNPCC accounts for 
some 10% of familial CRC it does not alone dominate familial risk (7, 8). Combined high-
penetrance genes are estimated to account for 14% of familial CRC and these include a number 
of genes with deleterious mutations (7, 9). Although CRC is known to be associated also with 
discordant familial cancers, such as endometrial and pancreatic cancers, only old data are 
available separately on colon cancer, associated with prostate, lung and breast cancers and rectal 
cancer, associated with prostate cancer and lymphocytic leukemia (10, 11). Data for associated 
discordant cancers may provide useful information about shared genetic and environmental risk 
factors. 
 
We apply here a novel approach to search for potential differences in familial associations of 
colon and rectal cancers with themselves and with other cancers using the most recent update of 
the Swedish Family-Cancer Database. The novelty involves assessment of familial IRRs for 
cancer X in families with increasing numbers of colon or rectal cancers, or conversely, familial 
IRRs for colon or rectal cancer in families with increasing numbers of cancers X. Our aim is to 
find true familial associations for which the risk would be assumed to increase by the number of 
affected family members. In earlier studies from Iceland and Utah true familial associations were 
searched by comparing familial risks in multiple generations which is possible if extended family 
data are available (12, 13).  We test also familial associations when a part of HNPCC related 






Swedish Family-Cancer Database (FCD) was created by combining the Multigeneration Register 
of Statistics Sweden, national Cancer Registry (started in 1958) and several other databases using 
unique national registration numbers. It includes all Swedish people born in 1932 or later 
(offspring generation) and their biological parents (parental generation). The FCD has so far 
been updated every two years and the latest version is FCD2012, including 15.7 million 
individuals. 
  
In the FCD, 1.8 million people (11.46%) were cancer patients diagnosed by the end of 2012. The 
3-digital codes of 7th revision of the International Classification of Diseases (ICD-7) were used 
to identify 36 most common cancers, including upper aerodigestive tract, salivary glands, 
esophagus, stomach, small intestine, colon, rectum, anus, liver, pancreas, nose, lung, breast, 
cervix, endometrium, uterus, ovary, other female genital, prostate, testis, other male genital, 
kidney, urinary bladder, melanoma, skin, eye, nervous system, thyroid gland, endocrine glands, 
bone, connective tissue, non-Hodgkin lymphoma, Hodgkin disease, myeloma, leukemia and 
cancer of unknown primary (CUP). According to the ICD-7 classification the demarcation of 
colon towards rectum is sigmoideum (code 153.3, part of colon) while for rectum no subsections 
are given.  
  
According to child-mother-father triplets in the FCD, nuclear families could be formed. Multiple 
primary cancer information was used to identify HNPCC families. A likely HNPCC family was 
defined as follows: at least one family member in a nuclear family had a double primary of CRC 
and any of the following cancers: endometrium, ovary, small intestine, pancreas, brain, liver, 
kidney and bladder cancers. The order of multiple primaries was not crucial but CRC was always 
to be present. We admit that the definition was too narrow to cover all HNPCC but we could not 
exclude familial CRC because it would have partially defeated the purpose of this study. 
Anyway, our reasoning was to observe whether removal of the putative HNPCC families 
reduced familial risks (suggesting HNPCC relation) or they remained unaltered (unlikely 




The individuals of offspring generation were followed up from the beginning of 1958, the birth 
year, or the immigration year, whichever came latest. They were followed up until diagnosis of 
cancer, emigration or death, or at the end of 2012, whichever came first. Incidence rates could be 
calculated by dividing the number of new cancer cases over a given time period by the sum of 
each individual’s person-years at risk. In this study we did not consider age of onset in spite of 
its known influence on familial risk (16). The reason was that we considered initially 36 different 
cancers for which the dependence of age is variable (17). Analysis of pairs of 36 different 
cancers by optimal ages would have been an utterly complex undertaking.   
 
The incidence rate ratio (IRR) were used as a measure of assessing familial risks by comparing 
incidence rates for persons with affected relatives to incidence rates for those whose relatives had 
no cancer (negative family history). First, IRR for cancer X when family history (the number of 
first degree relatives (FDRs) affected with cancer) was colon or rectal cancer: 
 
IRR = Incidence rate of X with family history of colon or rectal cancer            Incidence rate of X without family history of colon or rectal cancer            
Then, the reverse analysis: 
IRR = Incidence rate of colon or rectal cancer with family history of X           Incidence rate of colon or rectal cancer without family history of X            
 
Poisson regression model, which assumes that the dependent variable (e.g., the number of cancer 
cases in a cohort study) has a Poisson distribution, was applied to estimate IRRs, confidence 
intervals (CI) and trend tests. GENMOD procedure in SAS was used to do the analysis. For 
estimating IRRs, family history was an independent categorized variable (negative family 
history, 1 proband with cancer, or at least two probands with cancer). Age group (5-year bands), 
sex, calendar period (5-year bands), residential area (large cities, South Sweden, North Sweden, 
or unspecified) and socioeconomic status (blue collar worker, white collar worker, farmer, 
private, professional, or other/unspecified) were added to the model as covariates and person-
years were the offset. The group of negative family history was considered as the reference. As 
an example, to estimate IRR for colon cancer when one proband had rectal cancer, the incidence 
in such families was divided by the incidence of colon cancer in families with no family history 
of rectal cancer. Wald estimates were employed to calculate CI (95%, 99% and 99.9%). For 
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linear trend test, the model was refit. Since the number of probands with cancer was numeric, 
family history was regarded as continuous variable to test whether IRRs changed with the 
increasing number of probands with cancer and the other parameters in the model were 
unchanged.  
 
The Ethical Committee of Lund University approved this study protocol. 
 
RESULTS 
In the FCD, 8,635,688 individuals were enrolled and the total person-years at risk for the 
reference population were 286,060,994, with a mean follow-up of 33.1 years. 207,512 
individuals were diagnosed with colorectal cancer. Among these patients, 64.2% had colon 
cancer and 35.7% had rectal cancer. 22,320 colon cancer patients and 13,047 rectal cancer 
patients were in the offspring generation used as index individuals to calculate IRRs. In non-
HNPCC analysis (see Methods), 16,160 (0.37%) HNPCC families, including 41,201 individuals 
without cancer and 22,656 cancer patients, were excluded from 4,321,924 families found in the 
FCD.  
 
Four pairs of analysis were done to compare the concordant and discordant risks for colon and 
rectal cancers in all families (Table 1, upper part). The reference group was families without 
colon or rectal cancers in the FDRs. All IRRs in the first two columns (1 cancer case in the 
family or 2 cancer cases in the family) were increased at <0.1% confidence levels and the trend 
tests were highly significant. When one and two FDRs were affected with colon and/or rectal 
cancer, the adjusted IRRs for concordant colon cancer were the highest (1.92 and 3.91, 
respectively). The IRR for colon cancer was 5.60 in families with three FDRs diagnosed with 
CRC. IRRs were higher for CRC and colon cancer when FDRs were diagnosed with colon 
cancer than when FDRs were diagnosed with rectal cancer (CRC: 1.82 (95%CI 1.74-1.90) vs 
1.61 (95%CI 1.51-1.71) with non-overlapping 95%CI in families of one cancer, and 3.48 
(95%CI 2.96-4.10) vs 3.09 (95%CI 2.22-4.32) in families of two cancers; colon cancer: 1.92 
(95%CI 1.83-2.02) vs 1.56 (95%CI 1.45-1.69) with non-overlapping 95%CIs in families of one 
cancer, and 3.91(95%CI 3.24-4.71) vs 3.17 (95%CI 2.15-4.67) in families of two cancers). After 
excluding HNPCC families (Table 1, lower part), essentially all IRRs were slightly decreased 
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compared to all families. However, above significant differences between colon and rectal cancer 
with non-overlapping 95%CIs remained. 
 
Of a total of 36 cancers, 10 had increased discordant risks for colon or rectal cancers, or had 
significant trend tests (Table 2). For any cancer (including all 36 cancers) the IRRs increased by 
the number of FDRs affected with either colon or rectal cancer, or vice versa; for example colon 
cancer IRR was 1.19 in families of one cancer, 1.35 in families of two cancers. When proband 
cancer was either colon or rectal cancer, the IRRs of small intestinal cancer, pancreatic cancer, 
myeloma or ovarian cancer were increased or their trend tests were significant (pancreatic and 
ovarian cancers at 5% level). The IRRs of stomach, endometrial and thyroid gland cancers 
increased (all at 1% level) only when FDRs had colon cancer. In the reverse analysis, the IRRs 
of both colon and rectal cancers were increased by the number of FDRs were diagnosed with 
small intestinal (at 5% level), pancreatic, endometrial cancers or CUP (at 5% level). The IRRs of 
rectal cancer were increased when two FDRs had stomach (IRR=1.89) or thyroid gland cancer 
(IRR=7.08). The IRR of lung cancer increased at 5% level only when FDRs had rectal cancer 
(IRR=1.11), and in its reverse analysis only the trend test was significant (P=0.0499). The IRRs 
of nervous system tumors were significantly increased at 1% level when one FDR affected with 
colon cancer (IRR=1.11) and in the reverse analysis (IRR=1.16). Of note, none of the IRRs 
differed significantly between colon and rectal cancers (i.e., 95%CIs overlapped). In the colon 
and rectal cancer families presenting with small intestinal cancer equal numbers of small 
intestinal adenocarcinomas and carcinoids were found. In the one proband families all significant 
association of Table 2 were with adenocarcinomas and IRRs increased to about 1.7. Associations 
with carcinoids were not significant, with the exception of the 5 cases in the two proband 
families which were all carcinoids (IRR=10.45; 95%CI: 4.59-23.83).    
 
The discordant risks for colon and rectal cancer were also estimated in non-HNPCC families 
(Table 3). For endometrial, ovarian cancer and their reverse analysis, the IRRs and trend test 
were no longer significant. The IRRs of any cancer and their reverse analysis were slightly 
decreased compared to Table 2.  For other cancers there were no essential differences between 
Tables 3 and 2. The IRRs of colon cancer were marginally higher in non-HNPCC families, when 
FDRs were diagnosed with CUP (1.15 vs 1.14 and 1.78 vs 1.62) or pancreatic cancer (1.18 vs 
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1.17 and 0.82 vs 0.76); the IRRs of rectal cancer were higher, when FDRs were diagnosed with 
CUP (1.16 vs 1.15 and 1.27 vs 1.19) or thyroid gland (1.08 vs 1.07 and 7.55 vs 7.08) cancer. 
When FDRs had rectal cancer, the IRRs of small intestinal cancer (1.16 vs 1.13 and 6.04 vs 5.24) 
and myeloma (1.24 vs 1.22 and 1.00 vs 0.89) were also slightly increased. 
 
DISCUSSION 
The recent study is the largest single family study on colon and rectal cancers. Although the 
colon and the rectum are often combined to the colorectum, they have very different functions. 
The colon absorbs nutrient and water, while rectum stores feces (18). Studies have also found 
that the etiology of colon cancer differ from that of rectal cancer. For instance, the alteration of 
mismatch repair (MMR) genes and adenomatous polyposis coli (APC) gene favor the 
development of colon cancer, whereas the cyclooxygenase COX-2 responsible for the synthesis 
of prostaglandinE2 (PGE2) is overexpressed mainly in rectal cancer (19). In addition, several 
environmental factors, such as physical activity and dietary fiber, are associated with colon 
cancer but less or null with rectal cancer (18). A family history of CRC is regarded as a risk 
factor for colon and rectal cancer (20). Wei et al found that the RRs of colon and rectal cancer 
were increased to 1.94 and 1.27 respectively (2). However, few studies have separated CRC as 
two cancer sites (colon and rectum) and reported separate family histories. In our study, four 
pairs of comparison were carried out to analyze the relationship between CRC, colon and rectal 
cancers. There were significant familial associations among CRC, colon and rectal cancers, and 
for most associations colon and rectal cancers did not differ. Although the IRRs of CRC and 
colon cancer were statistically higher in colon cancer families compared to rectal cancer families 
(IRR= 1.82 vs. 1.61 and 1.92 vs. 1.56) in families when 1 proband was diagnosed with cancer, 
the differences are modest. 
 
In analyses of discordant cancers, ten cancers were related to colon and/ or rectal cancers. 
However, an important conclusion from the present large study was that we found no strong 
statistical support distinguishing discordant familial associations of colon and rectal cancers. 
Overall discordant associations were somewhat stronger for colon than rectal cancer, which was 




For lung and nervous system cancers, the differences in IRRs between colon and rectal cancers 
were minor (overlapping 95%CI), yet only lung cancer was associated with rectal cancer with 
significant IRRs or trend tests and only nervous system cancer was associated with colon cancer 
with significant IRRs and trend tests. Therefore, the relationships of these two cancers to 
colorectal cancer were site-specific. The remaining eight cancer sites were related to both colon 
and rectal cancer. Since heavy smoking is thought to be a greater risk factor for rectal compared 
to colon cancer (21), the association between lung cancer and rectal cancer may be related to 
smoking. Lung cancer is reported to be associated with the rare Peutz-Jeghers syndrome, which 
is related to colon cancer but not rectal cancer (22). Thus no known syndromes may explain the 
association between lung cancer and rectal cancer. Brain cancer, accounted for a large part of 
nervous system cancer, is an extra-colonic cancer of at least two cancer syndromes (HNPCC and 
FAP) but the associations remained unchanged when patients with HNPCC related double 
primaries were removed (23). Among ten discordant cancer sites that were related to colon and/ 
or rectal cancers, myeloma and CUP did not belong to the known syndromes. Interestingly, 
familial associations of myeloma and CUP with each other, and a weaker association of 
myeloma and lung cancer have been found (24).    
 
Strengths of the study are a complete coverage of families and correct assignment of the family 
relationships, thanks to the Multigeneration Register. Similarly, cancers were obtained from a 
high-level nation-wide cancer registry (25). The weaknesses were limited power to find familial 
associations with rarer cancers and, because of lacking genetic and polyposis-related data, 
incomplete identification of HNPCC families or rare CRC related syndromes.  
 
CONCLUSION 
The present study showed that family history of colon cancer was a stronger risk factor than that 
of rectal cancer for CRC and colon cancers. For discordant cancers, lung cancer associated with 
rectal cancer and nervous system cancer with colon cancer. The discordant associations of with 
lung cancer, myeloma and CUP cannot be ascribed to the known syndromes. For the oncology 
clinic the message is that for the daily practice familial risks of colon and rectal cancers are 
similar and a family history alone does not easily distinguish HNPCC from other possible 
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Table 1 Discordant and concordant adjusted incidence rate ratios for colon and rectal cancers in all (upper 





  One proband with cancer   Two probands with cancer   At least three probands with cancer   Trend test 
P-value   Cases IRRa 95%CIb    Cases IRR 95%CI    Cases IRR 95%CI    
Colon 
CRC  
3063 1.81d (1.73--1.89)  249 3.10 (2.69--3.57)  24 5.60 (3.55--8.83)  <.0001
e 
Rectum  1723 1.68 (1.57--1.80)  132 2.71 (2.15--3.42)  12 4.66 (2.17--10.01)  <.0001 
CRC 
Colon  3335 1.82 (1.74--1.90)  202 3.48 (2.96--4.10)  8 3.24
c (1.43--7.38)  <.0001 
Rectum  1778 1.61 (1.51--1.71)  60 3.09 (2.22--4.32)  0 . .  <.0001 
Colon 
Colon  2184 1.92 (1.83--2.02)  140 3.91 (3.24--4.71)  6 3.90 (1.59--9.57)  <.0001 
Rectum  1078 1.56 (1.45--1.69)  38 3.17 (2.15--4.67)  0 . .  <.0001 
Rectum 
Colon  1151 1.67 (1.53--1.82)  62 2.86 (2.00--4.11)  2 2.21 (0.30--16.37)  <.0001 
Rectum  700 1.70 (1.51--1.92)  22 3.06 (1.59--5.88)  0 . .  <.0001 
Colon 
CRC  
2579 1.72 (1.64--1.81)  175 2.66 (2.23--3.16)  11 3.75 (1.88--7.47)  <.0001 
Rectum  1501 1.62 (1.52--1.73)  107 2.63 (2.11--3.27)  7 3.86 (1.64--9.06)  <.0001 
CRC 
Colon   2817 1.74 (1.67--1.82)   133 2.89 (2.39--3.51)   2 1.30 (0.27--6.22)   <.0001 
Rectum  1520 1.55 (1.45--1.65)  47 2.90 (2.00--4.19)  0 . .  <.0001 
Colon 
Colon  1820 1.83 (1.73--1.93)  88 3.12 (2.45--3.98)  0 . .  <.0001 
Rectum  905 1.49 (1.37--1.62)  32 3.20 (2.06--4.96)  0 . .  <.0001 
Rectum 
Colon  997 1.61 (1.48--1.76)  45 2.58 (1.75--3.79)  2 3.43 (0.55--21.31)  <.0001 
Rectum  615 1.66 (1.50--1.83)  15 2.46 (1.31--4.64)  0 . .  <.0001 
a: IRR=incidence rate ratio; 
b: CI=confidence interval; 
c: Bold and underlined value denotes significantly increased RR at the two-sided 1% level; 
d: Bold, underlined and Italics value denotes significantly increased RR at the two-sided 0.1% level; 











  One proband with cancer   Two probands with cancer   Trend test 
P-value   Cases IRRa 95%CIb    Cases IRR 95%CI    
Stomach Colon  332 1.15
c (1.02--1.30)  19 2.06
d (1.28--3.32)  0.0021
f 
Rectum  168 0.97 (0.84--1.13)  1 0.32 (0.05--2.23)  0.5142 
Colon Stomach  732 1.05 (0.70--1.57)  11 1.04 (0.04--26.27)  0.8109 Rectum  446 1.07 (0.97--1.17)  12 1.89 (1.07--3.32)  0.0737             Small 
intestine 
Colon  133 1.39
e (1.16--1.66)  3 1.03 (0.33--3.20)  0.0006 
Rectum  64 1.13 (0.87--1.46)  5 5.24 (2.10--13.08)  0.1623 
Colon Small 
intestine  
98 1.31 (1.04--1.64)  0 . .  0.0275 
Rectum  62 1.38 (1.05--1.82)  0 . .  0.0305             
Pancreas Colon  398 1.12 (0.99--1.26)  16 1.37 (0.77--2.44)  0.0378 Rectum  243 1.15 (0.97--1.35)  6 1.51 (0.54--4.25)  0.0909 
Colon Pancreas  546 1.17 (1.07--1.27)  4 0.76 (0.29--2.01)  0.0008 Rectum  315 1.12 (1.00--1.26)  9 2.76 (1.40--5.46)  0.0224             
Lung Colon  1389 1.04 (0.97--1.13)  38 0.88 (0.56--1.38)  0.3892 Rectum  875 1.11 (1.02--1.21)  14 0.96 (0.49--1.88)  0.0282 
Colon Lung  1221 1.06 (1.00--1.13)  44 1.10 (0.80--1.53)  0.0620 Rectum  751 1.09 (1.00--1.18)  26 1.07 (0.69--1.66)  0.0499             
Endometrium Colon  707 1.14 (1.02--1.27)  37 1.87 (1.17--2.98)  0.0074 Rectum  369 1.00 (0.89--1.13)  12 1.87 (1.00--3.51)  0.6174 
Colon Endometrium  594 1.27 (1.14--1.41)  14 2.41 (1.24--4.71)  <.0001 Rectum  318 1.13 (1.00--1.26)  7 1.93 (0.89--4.22)  0.0311             
Ovary Colon  555 1.07 (0.98--1.18)  23 1.49 (0.97--2.30)  0.0476 Rectum  340 1.12 (1.01--1.24)  6 1.22 (0.57--2.59)  0.0258 
Colon Ovary  419 1.07 (0.98--1.18)  2 0.54 (0.14--2.10)  0.1980 Rectum  266 1.13 (0.99--1.30)  4 1.72 (0.57--5.18)  0.0632             Nervous 
system 
Colon  1053 1.11 (1.04--1.19)  37 1.41 (0.98--2.03)  0.0011 
Rectum  580 1.04 (0.95--1.14)  11 1.31 (0.70--2.47)  0.2900 
Colon Nervous 
system  
560 1.16 (1.05--1.27)  7 1.03 (0.45--2.34)  0.0107 
Rectum  325 1.12 (0.98--1.29)  1 0.24 (0.02--2.66)  0.1740             Thyroid 
gland 
Colon  298 1.19 (1.05--1.35)  9 1.33 (0.65--2.72)  0.0072 
Rectum  168 1.14 (0.97--1.34)  3 1.39 (0.43--4.49)  0.0972 
Colon Thyroid 
gland  
140 1.04 (0.88--1.21)  2 2.78 (0.74--10.44)  0.5095 
Rectum  86 1.07 (0.87--1.31)  3 7.08 (2.40--20.88)  0.2951             
Myeloma Colon  256 1.14 (1.02--1.28)  11 1.58 (0.93--2.67)  0.0076 Rectum  160 1.22 (1.06--1.41)  2 0.89 (0.25--3.14)  0.0104 
Colon Myeloma  276 1.10 (0.97--1.24)  3 1.50 (0.46--4.84)  0.1283 Rectum  151 1.00 (0.85--1.18)  0 . .  0.9978             
CUPg Colon  475 0.97 (0.83--1.15)  23 1.46 (0.70--3.01)  0.9487 Rectum  319 1.10 (0.89--1.37)  7 1.31 (0.32--5.37)  0.3389 
Colon CUP  629 1.14 (1.01--1.27)  9 1.62 (0.66--3.98)  0.0186 Rectum  383 1.15 (1.00--1.33)  4 1.19 (0.30--4.67)  0.0502             
Any  Colon  24541 1.11 (1.08--1.13)  941 1.37 (1.20--1.55)  <.0001 Rectum  14153 1.09 (1.05--1.13)  260 1.19 (0.90--1.58)  <.0001 
Colon Any  9058 1.19 (1.15--1.23)  3724 1.35 (1.29--1.41)  <.0001 Rectum   5381 1.17 (1.12--1.23)   2190 1.29 (1.22--1.38)   <.0001 
            Any 
discordant 
Colon  21206 1.05 (1.02--1.08)  739 1.20 (1.04--1.38)  <.0001 
Rectum  12375 1.05 (1.00--1.09)  200 1.02 (0.74--1.42)  0.0365 
Colon Any 
discordant 
 8635 1.09 (1.05--1.12)  2833 1.12 (1.07--1.18)  <.0001 
Rectum  5066 1.06 (1.01--1.11)  1704 1.11 (1.04--1.18)  <.0001 
a: IRR=incidence rate ratio; 
b: CI=confidence interval; 
c: Bold type denotes significantly increased RR at the two-sided 5% level; 
d: Bold and underlined value denotes significantly increased RR at the two-sided 1% level; 
e: Bold, underlined and Italics value denotes significantly increased RR at the two-sided 0.1% level; 
f: Bold type denotes that trend test was statistically significant; 
g: CUP=cancer of unknown primary. 
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 One proband with cancer  Two proband with cancer  Trend test 
P-value 
 Cases IRR
a 95%CIb  Cases IRR 95%CI  
Stomach Colon  306 1.13 (1.00--1.28)  16 2.06
d (1.22--3.49)  0.0091
f 
Rectum  158 0.97 (0.83--1.13)  1 0.36 (0.05--2.58)  0.4976 
Colon Stomach  672 1.05 (0.69--1.59)  11 1.12 (0.04--28.37)  0.8317 Rectum  420 1.07 (0.97--1.17)  12 1.99
c (1.14--3.47)  0.0730             Small 
intestine 
Colon  114 1.30 (1.09--1.55)  2 0.83 (0.23--3.02)  0.0096 
Rectum  61 1.16 (0.89--1.51)  5 6.04
e (2.42--15.05)  0.1131 
Colon Small 
intestine  
86 1.28 (1.00--1.63)  0 . .  0.0600 
Rectum  57 1.38 (1.03--1.84)  0 . .  0.0380             
Pancreas Colon  362 1.09 (0.95--1.25)  13 1.32 (0.65--2.68)  0.1798 Rectum  240 1.20 (1.00--1.43)  4 1.14 (0.29--4.40)  0.0447 
Colon Pancreas  510 1.18 (1.08--1.29)  4 0.82 (0.31--2.19)  0.0004 Rectum  301 1.14 (1.01--1.28)  8 2.60 (1.27--5.33)  0.0177             
Lung Colon  1295 1.04 (0.95--1.13)  34 0.94 (0.55--1.58)  0.4552 Rectum  824 1.10 (1.01--1.20)  12 0.93 (0.45--1.91)  0.0504 
Colon Lung  1121 1.06 (0.99--1.13)  42 1.14 (0.82--1.59)  0.0791 Rectum  706 1.08 (0.99--1.18)  24 1.05 (0.67--1.66)  0.0777             
Endometrium Colon  607 1.07 (0.94--1.21)  25 1.52 (0.82--2.82)  0.2222 Rectum  335 0.98 (0.88--1.10)  6 1.08 (0.48--2.39)  0.8048 
Colon Endometrium  467 1.11 (0.98--1.26)  9 1.78 (0.73--4.32)  0.0875 Rectum  284 1.10 (0.97--1.24)  6 1.86 (0.81--4.28)  0.1022 
            
Ovary Colon  490 1.03 (0.94--1.13)  15 1.17 (0.70--1.94)  0.4346 Rectum  311 1.10 (0.99--1.23)  5 1.15 (0.50--2.65)  0.0790 
Colon Ovary  373 1.05 (0.96--1.16)  2 0.60 (0.16--2.30)  0.3714 Rectum  246 1.13 (0.98--1.30)  4 1.85 (0.61--5.56)  0.0795             Nervous 
system 
Colon  967 1.10 (1.02--1.18)  30 1.36 (0.89--2.06)  0.0079 
Rectum  537 1.03 (0.93--1.12)  10 1.36 (0.70--2.64)  0.4889 
Colon Nervous 
system  
518 1.17 (1.06--1.29)  6 0.97 (0.39--2.38)  0.0105 
Rectum  297 1.10 (0.93--1.29)  0 . .  0.2867             Thyroid 
gland 
Colon  275 1.18 (1.03--1.36)  6 1.05 (0.42--2.59)  0.0214 
Rectum  153 1.10 (0.93--1.30)  3 1.57 (0.49--5.00)  0.2193 
Colon Thyroid 
gland  
132 1.06 (0.90--1.25)  1 1.54 (0.23--10.31)  0.4616 
Rectum  82 1.08 (0.88--1.33)  3 7.55 (2.62--21.77)  0.2569             
Myeloma Colon  237 1.13 (1.01--1.27)  9 1.53 (0.87--2.68)  0.0147 Rectum  154 1.24 (1.07--1.44)  2 1.00 (0.28--3.57)  0.0062 
Colon Myeloma  253 1.09 (0.96--1.24)  3 1.62 (0.49--5.29)  0.1721 Rectum  144 1.01 (0.86--1.19)  0 . .  0.9083             
CUPg Colon  438 0.96 (0.81--1.13)  20 1.50 (0.71--3.17)  0.9468 Rectum  302 1.10 (0.91--1.33)  6 1.26 (0.34--4.73)  0.2916 
Colon CUP  586 1.15 (1.02--1.29)  9 1.78 (0.72--4.41)  0.0157 Rectum  364 1.16 (1.00--1.34)  4 1.27 (0.32--5.02)  0.0491             
Any  Colon  22405 1.09 (1.06--1.12)  738 1.28 (1.11--1.48)  <.0001 Rectum  13159 1.08 (1.04--1.12)  220 1.15 (0.84--1.56)  0.0002 
Colon Any  8357 1.17 (1.13--1.22)  3303 1.29 (1.23--1.36)  <.0001 Rectum   5076 1.16 (1.11--1.21)   2003 1.26 (1.18--1.33)   <.0001 
            Any 
discordant 
Colon  19588 1.04 (1.01--1.07)  605 1.16 (0.99--1.36)  0.0019 
Rectum  11639 1.04 (1.00--1.09)  173 1.00 (0.70--1.42)  0.0680 
Colon Any 
discordant 
 7953 1.08 (1.04--1.12)  2570 1.10 (1.05--1.17)  <.0001 
Rectum  4779 1.05 (1.01--1.11)  1596 1.10 (1.03--1.17)  <.0001 
a: IRR=incidence rate ratio; 
b: CI=confidence interval; 
c: Bold type denotes significantly increased RR at the two-sided 5% level; 
d: Bold and underlined value denotes significantly increased RR at the two-sided 1% level; 
e: Bold, underlined and Italics value denotes significantly increased RR at the two-sided 0.1% level; 
f: Bold type denotes that trend test was statistically significant; 
g: CUP=cancer of unknown primary. 
